アジスロマイシン研究によるアフリカの乳児ケアの改善 (ICARIA)
シエラレオネにおける拡大予防接種プログラムを通じて投与されたアジスロマイシンと間欠的予防治療の小児死亡率への影響の評価
Infectious diseases are among the most common causes of mortality in the over 2.5 million children under 5 years of age (U5) who died in 2018 in sub-Saharan Africa (SSA). New approaches to treatment and prevention of these diseases are needed to increase child survival. Sierra Leone has one of the highest rates of under-five child mortality in the world. It is estimated that 32,000 children die each year, the leading causes being neonatal conditions, malaria, pneumonia and diarrhea. In Sierra Leone, the available information on malaria indicates that it accounts for 38% of deaths among under-five children. Reducing the prevalence and impact of the disease among the general population is a major priority of the Ministry of Health and Sanitation (MoHS) of Sierra Leone .
Intermittent Preventative Treatment in infants (IPTi) - the administration of a full course antimalarial treatment to infants at individual timepoints regardless of infection status- has been shown to reduce clinical malaria and anemia in infants in the first year of life . When delivered alongside the Expanded Program on Immunization (EPI), IPTi with Sulphadoxine-pyrimethamine (SP) is a highly cost-effective intervention. . Sierra Leone is currently the only country that implements nationwide the World Health Organization's (WHO) IPTi guideline, which is administered within the first year of life. However, its benefit when expanded into the second year of life remains unknown. Taking the advantage of the inclusion in the EPI program of a booster dose of measles vaccine at 15 months of age, the ICARIA trial will also assess the efficacy of adding a dose of IPTi-SP at this age.
Recent studies show that azithromycin (AZi) - a macrolide antibiotic with some antimalarial effect- is associated with a significant reduction in childhood mortality when used in mass drug administration (MDA) for trachoma elimination in areas of sub-Saharan Africa (SSA) with child mortality rates far beyond Sustainable Development Goals , . However, despite the potential benefit of the intervention several fundamental scientific questions need to be answered before it can be recommended for large-scale implementation.
調査の概要
詳細な説明
In order to generate the conclusive evidence needed to inform policy and accelerate the implementation of this intervention, we propose to carry out a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through EPI. The potential development of antibiotic and SP resistance, AZi and SP interactions with routine immunizations, as well as the safety and the impact on the health system will be all assessed in the ICARIA trial.
To provide the evidence needed to inform policy and practice and to accelerate the implementation of this intervention, a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through the World Health Organisation Expanded Program on Immunisation (EPI) will be carried out in Sierra Leone. The clinical trial will be individually randomised, placebo-controlled with a factorial design whereby AZi will be administered alongside routine preventive health interventions of the EPI, such as immunisations and Intermittent Preventive Treatment in infants (IPTi), which is recommended by the WHO for malaria prevention in this age group. The potential development of antibiotic resistance, the interactions with routine immunisations, the safety and the impact on the health system of AZi administration will be all assessed in this trial.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Freetown、シエラレオネ
- College of Medicine and Allied Health Sciences
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Parents/guardians have signed the informed consent
- Permanent residence in the study area-health facility catchment area
- Without known allergies to or contraindications to macrolides
- Without known allergies to or contraindications to SP
- Agreement to complete the EPI scheme at the recruitment health facility
- Parents/guardians agree to participate
Exclusion Criteria:
- Residence outside the study area or planning to move out in the following 12 months from enrolment
- Known history of allergy or contraindications to macrolides and/or SP
- Known history of allergy or contraindications to SP
- With signs of any acute illness at the time of recruitment
- Participating in other intervention studies
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Group 1
AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age. |
Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
他の名前:
|
|
プラセボコンパレーター:Group 2
Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age. |
Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The rate of all-cause mortality
時間枠:18 months of age
|
all-cause mortality rate at 18 months of age |
18 months of age
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The cause-specific mortality rate
時間枠:18 months of age
|
Cause-specific mortality rate at 18 months of age |
18 months of age
|
|
Malaria related mortality
時間枠:18 month of age
|
Malaria related mortality at 18 months of age |
18 month of age
|
|
Incidence of all-cause hospital admissions
時間枠:Through study completion, 36 months
|
Incidence of all-cause hospital admissions |
Through study completion, 36 months
|
|
Incidence of all-cause outpatient attendances
時間枠:Through study completion, 36 months
|
Incidence of all-cause outpatient attendances at the health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (RDT positive) malaria hospital admissions
時間枠:Through study completion, 36 months
|
Incidence of confirmed (RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions
時間枠:Through study completion, 36 months
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Frequency and severity of drug adverse reactions
時間枠:Through study completion, 36 months
|
Frequency and severity of drug adverse reactions throughout the trial |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in nasopharyngeal isolates
時間枠:Through study completion, 36 months
|
Prevalence of macrolide resistance in nasopharyngeal isolates |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in the gut bacteria
時間枠:Through study completion, 36 months
|
Prevalence of macrolide resistance in the gut bacteria |
Through study completion, 36 months
|
|
Proportion of children with protective antibody responses to specific routine EPI immunizations (measles and yellow fever)
時間枠:Through study completion, 36 months
|
Proportion of children with protective antibody responses to specific routine EPI |
Through study completion, 36 months
|
協力者と研究者
協力者
捜査官
- 主任研究者:Clara Menendez, MD, PhD、Barcelona Institute for Global Health
出版物と役立つリンク
一般刊行物
- Chen H, Owusu-Kyei K, Fombah AE, Williams J, Garcia-Fernandez C, Rovira-Vallbona E, Bofill A, Quinto L, Figueroa-Romero A, Mac-Abdul F, Samai M, Mayor A, Menendez C. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone. Gates Open Res. 2025 Oct 8;9:81. doi: 10.12688/gatesopenres.16367.1. eCollection 2025.
- Owusu-Kyei K, Chen H, Chileshe M, Quinto L, Sibley M, Figueroa-Romero A, Llach M, Ramirez M, Bofill A, Samai M, Menendez C; ICARIA Trial Team. Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA). Trials. 2024 Sep 27;25(1):626. doi: 10.1186/s13063-024-08443-9.
- Chen H, Montero-Vale M, Owusu-Kyei K, Lara-Munoz A, Rubio-Garcia E, de Pedro-Jove R, Guiral E, Chileshe MN, Williams J, Bofill A, Samai M, Casals-Pascual C, Vila J, Menendez C. Early-life carriage and antibiotic resistance of Streptococcus pneumoniae in infants from Sierra Leone. Front Microbiol. 2026 May 22;17:1822296. doi: 10.3389/fmicb.2026.1822296. eCollection 2026.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- ICARIA
- OPP1196642 (その他の助成金/資金番号:Bill & Melinda Gates Foundation)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。